Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Gynecologic Oncology - Volume 148, Issue 3, March 2018, Pages 507-514

Heidi J. Gray, Katherine Bell-McGuinn, Gini F. Fleming, Mihaela Cristea, Hao Xiong, Danielle Sullivan, Yan Luo, Mark D. McKee, Wijith Munasinghe, Lainie P. Martin,